Small Cell Transformation in a Patient With RET Fusion-Positive Lung Adenocarcinoma on Pralsetinib

被引：6
|
作者：
Dimou, Anastasios [1 ]
Lo, Ying-Chun [2 ]
Merrell, Kenneth W. [3 ]
Halling, Kevin C. [2 ]
Mansfield, Aaron S. [1 ]
机构：
[1] Mayo Clin, Dept Oncol, Rochester, MN USA
[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[3] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA
来源：
JCO PRECISION ONCOLOGY | 2022年 / 6卷
关键词：
ACQUIRED-RESISTANCE; CANCER;
D O I：
10.1200/PO.22.00478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
    Griesinger, F.
    Curigliano, G.
    Thomas, M.
    Subbiah, V.
    Baik, C. S.
    Tan, D. S. W.
    Lee, D. H.
    Misch, D.
    Garralda, E.
    Kim, D. -W.
    van der Wekken, A. J.
    Gainor, J. F.
    Paz-Ares, L.
    Liu, S., V
    Kalemkerian, G. P.
    Houvras, Y.
    Bowles, D. W.
    Mansfield, A. S.
    Lin, J. J.
    Smoljanovic, V.
    Rahman, A.
    Kong, S.
    Zalutskaya, A.
    Louie-Gao, M.
    Boral, A. L.
    Mazieres, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (11) : 1168 - 1178
  • [32] An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)
    Nguyen, Vanessa Quang
    Geirnaert, Marc
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, : 450 - 456
  • [33] Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
    Gainor, Justin F.
    Curigliano, Giuseppe
    Kim, Dong-Wan
    Lee, Dae Ho
    Besse, Benjamin
    Baik, Christina S.
    Doebele, Robert C.
    Cassier, Philippe A.
    Lopes, Gilberto
    Tan, Daniel S. W.
    Garralda, Elena
    Paz-Ares, Luis G.
    Cho, Byoung Chul
    Gadgeel, Shirish M.
    Thomas, Michael
    Liu, Stephen, V
    Taylor, Matthew H.
    Mansfield, Aaron S.
    Zhu, Viola W.
    Clifford, Corinne
    Zhang, Hui
    Palmer, Michael
    Green, Jennifer
    Turner, Christopher D.
    Subbiah, Vivek
    [J]. LANCET ONCOLOGY, 2021, 22 (07): : 959 - 969
  • [34] Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
    Lin, J. J.
    Liu, S., V
    McCoach, C. E.
    Zhu, V. W.
    Tan, A. C.
    Yoda, S.
    Peterson, J.
    Do, A.
    Prutisto-Chang, K.
    Dagogo-Jack, I
    Sequist, L., V
    Wirth, L. J.
    Lennerz, J. K.
    Hata, A. N.
    Mino-Kenudson, M.
    Nardi, V
    Ou, S-H, I
    Tan, D. S-W
    Gainor, J. F.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (12) : 1725 - 1733
  • [35] RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond
    Wu, Jie
    Subbiah, Vivek
    [J]. CANCER RESEARCH, 2023, 83 (19) : 3159 - 3161
  • [36] Clinicopathologic features of advanced RET fusion-positive lung cancers and outcomes in comparison to other fusion-positive lung cancers
    Drilon, Alexander E.
    Hellmann, Matthew David
    Wang, Lu
    Cho, Eun Jung
    Ladanyi, Marc
    Rizvi, Naiyer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
    Velcheti, V.
    Hida, T.
    Reckamp, K. L.
    Yang, J. C.
    Nokihara, H.
    Sachdev, P.
    Feit, K.
    Kubota, T.
    Nakada, T.
    Dutcus, C. E.
    Ren, M.
    Tamura, T.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [38] RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future
    Chen, Monica F.
    Repetto, Matteo
    Wilhelm, Clare
    Drilon, Alexander
    [J]. DRUGS, 2024, 84 (09) : 1035 - 1053
  • [39] Pralsetinib in RET fusion-positive non-small cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)
    Passaro, A.
    Lo Russo, G.
    Passiglia, F.
    D'Arcangelo, M.
    Sbrana, A.
    Russano, M.
    Bonanno, L.
    Giusti, R.
    Metro, G.
    Bertolini, F.
    Grisanti, S.
    Carta, A.
    Cecere, F. L.
    Montrone, M.
    Massa, G.
    Attili, I.
    de Marinis, F.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1065 - S1065
  • [40] Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
    Fangdi Sun
    Caroline E. McCoach
    [J]. Current Treatment Options in Oncology, 2021, 22
12345